Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963603 | 0.98 | POLB (0.36) | POLBCYP1A2GAAMAPTTDP1 | |
| SCHEMBL13415330 | 0.98 | POLB (0.36) | POLBCYP1A2GAAMAPTTDP1 | |
| SCHEMBL24438544 | 0.98 | POLB (0.36) | POLBCYP1A2GAAMAPTTDP1 | |
| SCHEMBL24438561 | 0.98 | POLB (0.36) | POLBCYP1A2GAAMAPTTDP1 | |
| SCHEMBL19038311 | 0.95 | — | — | |
| SCHEMBL19443230 | 0.84 | — | — | |
| SCHEMBL25777199 | 0.81 | NOS1 (0.31) | — | |
| SCHEMBL19576178 | 0.80 | — | — | |
| SCHEMBL21011044 | 0.80 | TP53 (0.33) | TP53 | |
| SCHEMBL22597998 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778012-A | Stripping liquid composition for IGZO substrate, preparation method thereof and semiconductor element | 易安爱富科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117784538-A | Stripping liquid composition for IGZO substrate, preparation method thereof and semiconductor device | 易安爱富科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3694858-B1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-01-11 | — | — | EP | disclosed |
| CN-115079523-A | Stripping liquid composition and preparation method thereof | 易安爱富科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2019-05-16 | — | — | US | disclosed |
| WO-2019072942-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-7687500-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687500-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | HOWELL AMY R | 2008-06-12 | — | — | US | disclosed |
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | HOWELL AMY R | 2008-06-12 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | PNP, TYMP, DHPS | POLB 532/4885CYP1A2 1263/4885GAA 872/4885 |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | POLB 3348/4885CYP1A2 4596/4885GAA 4640/4885 |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | POLB 3348/4885CYP1A2 4596/4885GAA 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.